Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMVP Health Care Papzimeos Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentMVP Health CarePolicy N/A

    Medicare Part B: Zopapogene imadenovec (Papzimeos)

    Customize your policy alerts

    Sign up for all MVP Health Care policy alerts

    Know when MVP Health Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Medicare Part B coverage and prior authorization requirements for Papzimeos (zopapogene imadenovec-drba) administered under the medical benefit. It applies to members seeking treatment for recurrent respiratory papillomatosis.

    Policy Summary
    PayerMVP Health Care
    PolicyMedicare Part B: Zopapogene imadenovec (Papzimeos)
    Policy CodePolicy N/A
    Change TypeInitial policy
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionSubmit chart notes confirming a diagnosis of recurrent respiratory papillomatosis.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4 dosesDoses in one treatment course
    12 weeksTreatment course interval
    1 courseMaximum covered courses
    RRPCovered disease indication

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Initial treatment course

    Papzimeos may be considered for coverage when all of the following are provided:

    Required coverage conditions

    • Diagnosis: Chart notes confirm a diagnosis of recurrent respiratory papillomatosis (RRP).
    • Specialist oversight: Papzimeos is prescribed by or in consultation with an appropriate specialist, such as an otolaryngologist, laryngologist, oncologist, or pulmonologist.
    • Treatment history: The member has not received a previous treatment course of Papzimeos.
    • Surgical debulking: The provider attests that surgical debulking of visible papilloma is performed before the initial, third, and fourth doses of Papzimeos.Before doses 1, 3, and 4
    • Treatment-course limit: Treatment is limited to one course within a 6-month period.4 doses over a 12-week interval; one course within 6 months

    Coverage is limited to one completed Papzimeos treatment course. Extensions beyond that course are excluded, and more than one lifetime treatment course—defined as 4 doses over a 12-week interval—is not covered.

    Papzimeos is not covered when the requested use is outside FDA-approved package labeling for age, dose, dosing frequency, or treatment duration.

    Initial Therapy Criteria

    Initial Papzimeos treatment

    Papzimeos may be considered for coverage when all of the following are provided:

    Initial Papzimeos coverage criteria

    • Documented indication: Chart notes confirm a diagnosis of recurrent respiratory papillomatosis (RRP).
    • Appropriate specialist involvement: Papzimeos is prescribed by or in consultation with an appropriate specialist, such as an otolaryngologist, laryngologist, oncologist, or pulmonologist.
    • No previous Papzimeos course: The member has not received a previous treatment course of Papzimeos.
    • Required surgical debulking: The provider attests that surgical debulking of visible papilloma is performed before the initial, third, and fourth doses of Papzimeos.Before doses 1, 3, and 4
    • Course limitation: Papzimeos is limited to one treatment course within a 6-month period.4 doses over a 12-week interval; one course within 6 months

      Extensions beyond one completed treatment course are excluded from coverage.

    Continuation Criteria

    No covered extension beyond one course

    Continuation or extension beyond one completed treatment course is not covered. Coverage is not available when any of the following applies:

    Noncovered continuation or extension

    • More than one lifetime course: More than one Papzimeos treatment course is requested or provided.No more than one course per lifetime
    • Extension beyond one course: An extension beyond one completed Papzimeos treatment course is requested.
    • Outside FDA-approved labeling: The requested age, dose, dosing frequency, or duration of therapy is outside FDA-approved package labeling.

    Coding and Treatment Course Parameters

    Drugs Requiring Prior Authorization under the medical benefitHCPCSCovered
    J3404Papzimeos (injection, zopapogene imadenovec-drba suspension, per therapeutic dose)
    Papzimeos treatment course
    Dose count4 doses
    Treatment intervalOver a 12-week interval
    Course periodOne treatment course within a 6-month period
    Lifetime treatment limit
    Maximum covered coursesNo more than one treatment course per lifetime
    Doses per course4 doses
    Interval per courseWithin a 12-week interval

    Provider Documentation and Authorization

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required under the medical benefit for Papzimeos (J3404). Submit the request with supporting clinical documentation before administration.

    • Medical-benefit drug code: J3404 — zopapogene imadenovec-drba suspension, per therapeutic dose.
    • Papzimeos is administered by the pharmacy department; refer to MVP Medicare Part D policies separately for Part D coverage.
    Documentation Required

    Diagnosis Confirmation Required

    Coverage requires chart notes confirming a diagnosis of recurrent respiratory papillomatosis (RRP).

    • Submit current clinical documentation supporting the RRP diagnosis.
    Documentation Required

    Specialist Involvement Required

    Papzimeos must be prescribed by, or used in consultation with, an appropriate specialist.

    • Examples include an otolaryngologist, laryngologist, oncologist, or pulmonologist.
    • Document the prescribing specialist or the specialist consultation in the medical record.
    Documentation Required

    Treatment History Must Be Confirmed

    Confirm that the member has not received a previous treatment course of Papzimeos.

    • Papzimeos is limited to one treatment course within a 6-month period.
    • One treatment course consists of 4 doses over a 12-week interval.
    Documentation Required

    Surgical Debulking Required

    The provider must attest that surgical debulking of visible papilloma is performed before the specified Papzimeos doses.

    • Surgical debulking must occur before the initial dose, third dose, and fourth dose.
    Denial Risk

    Excessive or Non-Labeled Treatment May Be Denied

    Coverage is excluded for excessive treatment or use outside FDA-approved package labeling. Requests for extensions beyond one completed treatment course are not covered.

    • More than one treatment course—4 doses within a 12-week interval—per lifetime is not covered.
    • Age, dose, dosing frequency, or duration outside FDA-approved package labeling is not covered.
    Denial Risk

    Missing Clinical Documentation May Result in Denial

    Requests may be denied when required clinical documentation is missing or does not establish eligibility for coverage.

    • Provide chart notes confirming RRP.
    • Document prescribing by or consultation with an appropriate specialist.
    • Confirm the member has not received a previous Papzimeos treatment course.
    • Include provider attestation of surgical debulking before the initial, third, and fourth doses.

    Clinical Background

    Recurrent respiratory papillomatosis (RRP) is a rare, benign neoplastic disease caused by chronic infection with human papillomavirus (HPV), most commonly types 6 or 11. It causes recurrent papilloma growth throughout the aerodigestive tract, most often affecting the larynx and trachea and, occasionally, the lungs.

    Definitions

    Recurrent respiratory papillomatosis (RRP)
    DiseaseRecurrent respiratory papillomatosis (RRP)
    CauseA chronic infection with human papillomavirus (HPV) types 6 or 11
    DefinitionA rare, benign neoplastic disease characterized by recurrent growth of papillomas throughout the aerodigestive tract
    Zopapogene imadenovec (Papzimeos)
    TherapyZopapogene imadenovec (Papzimeos)
    Mechanism classificationNonreplicating adenoviral vector-based immunotherapy
    TargetGenerates an immune response against HPV 6- and HPV 11-infected cells

    Quantity and Lifetime Limits

    Papzimeos quantity limits
    Course dose count4 doses
    Course durationOver a 12-week interval
    Lifetime quantity limitNo more than one treatment course per lifetime
    Policy Summary
    PayerMVP Health Care
    PolicyMedicare Part B: Zopapogene imadenovec (Papzimeos)
    Policy CodePolicy N/A
    Change TypeInitial policy
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionSubmit chart notes confirming a diagnosis of recurrent respiratory papillomatosis.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation CriteriaCoding and Treatment Course ParametersProvider Documentation and AuthorizationClinical BackgroundDefinitionsQuantity and Lifetime Limits